SentiAR announced today that it has received an invitation from Microsoft Corp. to participate in their Mixed Reality Partnership Program (MRPP). The program identifies solution provider partners who are committed to building mixed reality solutions in targeted industries, including healthcare. Inclusion into the program will provide SentiAR with access to a variety of Microsoft development tools, programs and services to assure positive business outcomes for participants.
The Mixed Reality Partnership Program was initiated by Microsoft shortly after introducing HoloLens in 2015. Under Microsoft’s oversight, the program identifies a structured framework in key areas to assure application and business success for its provider partners. A variety of technical and marketing training opportunities and resources are made available to partner participants selected into the program. Microsoft then works with the solution provider partners during their commercialization journey to assure that key deliverables are completed and access to Microsoft technical and business development resources are provided.
“SentiAR’s use case demonstrates the potential of the technology to improve patient outcomes,” said Simon Kos, MD, Chief Medical Officer at Microsoft. “We look forward to working with and learning from their team of pioneering leaders and together defining the possibilities for Microsoft HoloLens and mixed reality in health.”
About SentiAR, Inc.
SentiAR, Inc., based in St. Louis, MO., is developing and commercializing a 3D augmented reality visualization solution for intraoperative use by an Electrophysiologist during an ablation/mapping procedure of the heart. The SentiAR system takes real-time electro anatomic mapping system imagery and correlating catheter position data and provides 3D holograph images to the clinician user. Spatial navigation and acuity of images is achieved using gaze and voice commands to self-manipulate the scale, rotation, and positioning of the imagery to the preferred user perspective. The product is currently limited by federal law to investigational use only. SentiAR is planning on submitting the product to the FDA for their review this fall.